RxDoctor Payments Data

Senthil Nachimuthu, MD

Clinical Cardiac Electrophysiology · Stillwater, OKNPI 1235246018

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $7,609 of the $12,071 with a category attached, or 63.0%. 33 manufacturers reported payments, led by Medtronic at 44.7% of the total. Reporting peaked in 2021 at $3,296 and has fallen 60.1% since, to $1,317 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in OK, where the typical reported total is $22,745.

$12,071in general payments, 2019–2025

Across 229 payments — averaging $52.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$4K
  • Novartis$362
  • Baylis Medical Company Inc$236
  • Pfizer$224
  • E.r. Squibb & Sons, L.L.C.$206
  • plus $1K from 27 others

What the payments were for

  • Travel & lodging$7,60963%
  • Food & beverage$4,46237%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,071 in reported general payments places this provider in the 20th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

See all clinical cardiac electrophysiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$229,341
Medicare patients
994
Services billed
3,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$234,863
EntrestoSacubitril/Valsartan154$118,364
XareltoRivaroxaban80$59,934
JardianceEmpagliflozin13$10,758
Dofetilide62$9,190
Flecainide Acetate154$4,641
Metoprolol Succinate271$2,767
ClopidogrelClopidogrel Bisulfate211$2,546
Amiodarone Hcl49$2,076
Prasugrel Hcl30$2,010
Pitavastatin Calcium14$1,933
Atorvastatin Calcium88$1,470
Metoprolol Tartrate181$1,207
Rosuvastatin Calcium125$1,137
Digoxin66$1,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$224$234,863309 claims
NovartisEntresto$362$118,364154 claims
Johnson & JohnsonXarelto$49$59,93480 claims
Boehringer IngelheimJardiance$19$10,75813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

Other clinical cardiac electrophysiology in Stillwater

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →